StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Genocea Biosciences has a 1 year low of $0.00 and a 1 year high of $0.00. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market cap of $6,000.00, a P/E ratio of 0.00 and a beta of 1.61.
About Genocea Biosciences
Recommended Stories
- Five stocks we like better than Genocea Biosciences
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.